8-K: AnaptysBio Discontinues UC Trial, Advances RA Program & Plans Split

AnaptysBio announced the discontinuation of its ulcerative colitis trial for rosnilimab due to lack of efficacy, while highlighting positive Phase 2b rheumatoid arthritis data and plans to separate into two publicly traded companies by year-end 2026.

Summary

• Rosnilimab's Phase 2 trial in moderate-to-severe ulcerative colitis (UC) failed to meet primary and key secondary endpoints at Week 12, leading to its discontinuation and an estimated $10 million in savings.
• Rosnilimab demonstrated a favorable safety and tolerability profile in the UC trial, with approximately 90% depletion of pathogenic T cells, consistent with its mechanism of action.
• The company plans to provide an update in H1 2026 on the advancement of rosnilimab in rheumatoid arthritis (RA), where it showed positive Phase 2b data, with future development to be funded by strategic or other capital sources without diluting existing royalties.
• AnaptysBio intends to separate its biopharma operations from its substantial royalty assets into two independent, publicly traded companies by year-end 2026.
• The Biopharma Co will focus on advancing ANB033 (CD122 antagonist) through Phase 1b in celiac disease and a second inflammatory indication, and ANB101 (BDCA2 modulator) through Phase 1a in healthy volunteers.
• The Royalty Management Co will manage rights to potential Jemperli royalties from GSK (projected >$390 million per year at peak sales >$2.7 billion before 2031) and Imsidolimab milestones and royalties from Vanda Pharmaceuticals.
• AnaptysBio anticipates ending 2025 with approximately $300 million in cash, including an expected accrual of a one-time $75 million commercial sales milestone from GSK in Q4 2025 once Jemperli achieves $1 billion in worldwide net sales.

Sentiment

Score: 6

Explanation: The failure of the UC trial is a significant negative, but it is offset by strong positive data for rosnilimab in RA, the substantial value of the royalty assets, and the strategic plan to separate the companies, which could unlock value. The cash position is also healthy.

Positives

• Rosnilimab's Phase 2b trial in rheumatoid arthritis (RA) met its primary endpoint (mean change from baseline in DAS28-CRP at Week 12) across all active doses, demonstrating "JAK-like efficacy" and a "best-in-disease profile" through 6 months.
• Rosnilimab showed deep, sustained reduction of pathogenic T cells (approximately 90% in synovial biopsies) and significant reduction of T and B cell activation, TNF, and IL-6 within the synovium in RA patients.
• RA responses were durable for at least 3 months off-drug, with 82% of Week 28 CDAI LDA responders maintaining response at Week 38.
• The company plans to separate into two independent, publicly traded companies by year-end 2026, aiming to unlock and maximize shareholder value.
• The Royalty Management Co will hold rights to substantial Jemperli royalties from GSK, projected to be over $390 million per year at peak sales exceeding $2.7 billion, expected before 2031.
• The Biopharma Co will retain a pipeline including ANB033, which has shown favorable safety, tolerability, and PK profile in Phase 1a, and promising preclinical data in celiac disease mouse models.
• ANB033 is being developed for celiac disease, a potential $4-5 billion U.S. market in non-responsive patients, and eosinophilic esophagitis, a potential $5 billion+ U.S. market.
• Anticipated cash balance of approximately $300 million by year-end 2025, including a $75 million commercial sales milestone from GSK.
• Imsidolimab (out-licensed to Vanda) has potential for $35 million in future milestones and 10% royalties on global net sales, with FDA BLA submission for GPP expected in Q4 2025.

Negatives

• Rosnilimab's Phase 2 trial in moderate-to-severe ulcerative colitis (UC) failed to meet its primary endpoint (mean change from baseline in modified Mayo Score) or key secondary endpoints of clinical response and clinical remission at Week 12.
• Rosnilimab performed no better than placebo in UC, with clinical remission achieved by only 7% of patients on active drug compared to placebo rates within expected historical ranges.
• Week 24 remission rates in the UC trial did not meet the company's six-month target product profile.
• The UC trial will be discontinued, indicating a setback for rosnilimab's broader inflammatory disease potential.

Risks

• The company's ability to advance its product candidates, obtain regulatory approval, and ultimately commercialize them.
• The timing and results of preclinical and clinical trials, which may not fully materialize or prove incorrect.
• The company's ability to fund development activities and achieve development goals.
• The company's ability to protect intellectual property.
• Risks and uncertainties described under the heading "Risk Factors" in documents filed with the SEC.
• The proposed separation into two companies involves risks and uncertainties regarding its structure, infrastructure, timing, and taxation.
• The potential to receive any royalties or milestone payments from the Vanda Pharmaceuticals license agreement is not guaranteed.
• Whether any of the company's product candidates will be best in class or optimized is uncertain.
• The potential to receive any additional milestones or royalties from the GSK collaboration and the timing thereof are subject to risks.
• The projected cash runway is based on assumptions that may not hold true.
• The RA market has significant co-morbidities, and commercial products have black box warnings for increased SAE incidence (e.g., infection, MACE, malignancy).

Future Outlook

The company plans to separate its biopharma operations from its royalty assets into two independent, publicly traded companies by year-end 2026 to maximize shareholder value. It will provide an update in H1 2026 on the advancement of rosnilimab in rheumatoid arthritis, with future development to be funded by strategic or other capital sources. ANB033 is expected to have top-line Phase 1b data in celiac disease in Q4 2026 and will initiate a Phase 1b in a second inflammatory indication in 2026. The company anticipates ending 2025 with approximately $300 million in cash, bolstered by an expected $75 million milestone from GSK.

Management Comments

• "Rosnilimab was safe and well tolerated, but we are disappointed in the lack of adequate efficacy and will discontinue the UC trial. However, we remain excited about the potential advancement of rosnilimab in RA and will provide an update in H1 2026 including funding by strategic or other sources of capital without diluting our royalties." Daniel Faga, President and CEO.
• "ANB033, our CD122 antagonist, is in a Phase 1b for celiac disease and we plan to announce a Phase 1b in another inflammatory disease in 2026. Simultaneously, we are reiterating our intention to separate our biopharma assets from our substantial royalty assets in 2026, including Jemperli royalties of >$390 million per year at GSKs peak sales guidance of >$2.7 billion, which Anaptys expects to be achieved before 2031." Daniel Faga, President and CEO.
• "Despite rosnilimab not being the appropriate therapeutic option for UC, biologic insights from these data will help further inform future rosnilimab development." Paul Lizzul, M.D., Ph.D., Chief Medical Officer.

Industry Context

The discontinuation of rosnilimab in ulcerative colitis highlights the high failure rate in drug development for complex autoimmune diseases, where placebo responses can be significant. However, the positive Phase 2b data for rosnilimab in rheumatoid arthritis positions it as a potential new mechanism of action in a substantial $20 billion U.S. market that has not seen a new therapeutic class since JAK inhibitors a decade ago. The company's strategy to separate its biopharma and royalty assets is a trend seen in the industry to unlock value and allow investors to align with different risk/reward profiles, especially given the significant and growing royalty stream from Jemperli. The development of ANB033 in celiac disease and EoE targets large unmet needs in markets with limited approved therapies.

Comparison to Industry Standards

• Rosnilimab's Phase 2b RA data demonstrated "JAK-like efficacy" through 6 months, comparing favorably to established JAK inhibitors like Rinvoq (upadacitinib) in terms of ACR50, ACR70, and CDAI LDA response rates in both b/tsDMARD-naive and experienced patients.
• In b/tsDMARD-naive patients, rosnilimab pooled doses showed 64% ACR50, 60% ACR70, and 48% CDAI LDA at Week 28, comparable to Rinvoq (SELECT-COMPARE) at 53% ACR50, 54% ACR70, and 35% CDAI LDA at Week 24/26.
• Rosnilimab's LDA response rates and durability are differentiated from Lilly's peresolimab (another CD122 antagonist), with rosnilimab showing greater depletion of PD-1high T cells and higher CDAI LDA rates (e.g., 57% pooled at Week 28 vs. 36-37% for peresolimab at Week 28).
• Rosnilimab's safety profile in RA was well tolerated with no safety signals, low rates of treatment discontinuation, and balanced serious/opportunistic infections, which compares favorably to commercial products like Xeljanz, Rinvoq, Humira, and Kevzara that carry black box warnings for increased SAE incidence (e.g., infections, MACE, malignancies).
• The observed ~90% depletion of pathogenic T cells in synovial biopsies for rosnilimab in RA is a strong translational proof of mechanism, indicating a potent on-target effect in the inflamed tissue.

Stakeholder Impact

• Shareholders: Potential for increased value through the proposed corporate separation, which aims to allow investors to align with different asset profiles (growth-oriented biopharma vs. royalty income stream). The UC trial failure may cause short-term negative sentiment, but the RA success and strong royalty assets provide a floor.
• Patients (UC): Discontinuation of rosnilimab means this therapeutic option will not be available for moderate-to-severe ulcerative colitis patients.
• Patients (RA): Positive Phase 2b data for rosnilimab offers hope for a new, effective treatment option with a differentiated mechanism of action and favorable safety profile in rheumatoid arthritis.
• Employees: The corporate separation will likely lead to restructuring, potentially impacting roles and responsibilities across the two new entities.
• Creditors (Sagard): The projected paydown of Jemperli receivables to Sagard between Q2 2027 and Q2 2028 indicates a clear path to fulfilling financial obligations.

Next Steps

• Provide an update in H1 2026 on the advancement of rosnilimab in RA, including funding by strategic or other sources of capital.
• Initiate a Phase 1b clinical trial in a second inflammatory indication with ANB033 in 2026.
• Anticipate top-line Phase 1b data for ANB033 in celiac disease in Q4 2026.
• Continue Phase 1a trial for ANB101 in healthy volunteers.
• FDA BLA submission for Imsidolimab in GPP expected in Q4 2025.
• Complete the proposed separation into two independent, publicly traded companies by year-end 2026.
• P3 enablement in RA for rosnilimab, including drug supply scale-up and end-of-phase 2 regulatory interactions.

Key Dates

Recommendation

The discontinuation of rosnilimab in ulcerative colitis is a negative development, but the strong positive Phase 2b data for rosnilimab in rheumatoid arthritis, coupled with the significant and growing royalty stream from Jemperli, provides a strong counterbalance. The planned corporate separation into a biopharma company and a royalty management company could unlock substantial shareholder value by allowing investors to choose their exposure to different risk/reward profiles. While the UC failure introduces uncertainty for one asset, the overall pipeline, particularly ANB033's potential, and the robust royalty income suggest a balanced outlook. A "hold" recommendation is appropriate as investors await further clarity on the corporate separation, Phase 3 plans for rosnilimab in RA, and ANB033's clinical progress.

Keywords

AnaptysBio, ANAB, Rosnilimab, Ulcerative Colitis, Rheumatoid Arthritis, ANB033, Celiac Disease, ANB101, BDCA2 modulator, Biotechnology, Clinical Trial, Phase 2, Phase 1b, Drug Development, Autoimmune Disease, Inflammatory Disease, SEC Filing, 8-K, Jemperli, GSK, Imsidolimab, Vanda Pharmaceuticals, Royalties, Corporate Separation, Biopharma, CD122 antagonist, Pathogenic T cell depleter, Eosinophilic Esophagitis